AI in Medicine News — 2026-10-04 (Sun)

Overview

- Mainly covers diagnosis/imaging (pancreatic cancer risk prediction, IVUS analysis, echocardiography, ECG) and management (coding automation, nurse schedules, insurer costs). - In clinical support, the American Academy of Pediatrics (AAP) announced guidelines for clinicians' use of generated AI. In terms of regulations, deficiencies in the systems in Bangladesh and Africa were pointed out. - In drug discovery, reports on Microsoft's "Quine" and Schrödinger's AI agent are hot topics. The stage (preclinical/clinical) is unclear from the headline.

Diagnosis/Image

- IVUS (Intravascular Ultrasound): A systematic review of automated analysis and interpretation using AI in coronary artery disease (Cureus). The level of evidence is reviewed. Individual performance values are not listed in the heading and are unknown. - Pancreatic cancer: Report that AI models can identify risks up to five years in advance (MedicalNewsToday). The "may" expression is the stage of risk prediction. Sensitivity and specificity are unknown. The verification stage is also unknown. - Echocardiography: Report that AI models have improved the accuracy of echocardiographic diagnosis (Medical Economics). The extent of improvement and target disease are unknown. - AI electrocardiogram (ECG): Smartphone tool reportedly detects potential heart disease (Intelligent Living). Target disease/performance unknown. - Tempus AI (TEM) only has a stock price information page and cannot read any information related to diagnosis.

Clinical decision support

- AAP: Published guidance on the use of generative AI by clinicians (Mirage News). Details of the contents are unknown. - Digital Health Wire: Discussion of integrating consumer AI into healthcare pathways. Specific measures are unknown. - Mount Sinai × Hasso Plattner Institute: Launch of graduate exchange program in the field of digital health and AI. This is an educational measure and there is no information regarding clinical performance. - Kerala (India): AI model predicts dengue risk in each district. Prediction accuracy and verification status are unknown.

Generation AI and medical documents/medical records

- AKASA: Announces autonomous mid-cycle AI for admission coding and clinical documentation improvement (CDI) (HIT Consultant, Unite.AI). Accuracy, number of installed facilities, and auditing system are not listed in the headline.

Hospital management/medical provision system

- Insurer costs: AI is costing insurers millions of dollars, reports Cleveland.com. Details of the breakdown and cause and effect are unknown. - Nurse schedules: AI-based schedule management causes confusion and nurses complain of safety issues (WIRED). No headline evidence of impact on patient outcomes. - AKASA's autonomous coding also falls under the operational domain (see Section 4).

Drug discovery/clinical trials

- Microsoft "Quine": Reports that competition among major tech companies has begun with entry into biopharmaceutical R&D (biggo). Stage/target unknown. - Schrödinger: Aiming to revolutionize drug discovery with AI agents (CMC Markets). Stage unknown. - Suvoda: Expanding AI functionality to integrated clinical trial platform. The stage of the trial is unknown due to support for clinical trial management. - CPRIT: CEO addresses disparity in AI ethics and cancer research funding (The Business Journals). It's not about research results. - Barron's Roundtable videos are market related and do not contain medical information.

Medical device approval/regulation

- Light AI “QuickScan Strep A”: Product development progress report (Lelezard). It is not an approval, designation, or guideline. Approval status is unknown. - Bangladesh: A research report states that the spread of AI medical images is outpacing the development of legislation. Not approval or designation, but findings based on research. - Approval/designation by regulatory authorities cannot be confirmed in this headline.

Safety/Error/Bias

- Africa CDC official: Points out that the African continent does not have the infrastructure to independently operate medical AI (The New Times). - See Section 5 for concerns about safety of nurse schedules. Regarding the delay in legal development in Bangladesh, see Section 7.

Research results (major journals)

- There is no relevant information reported in major journals (peer-reviewed journals). For the Cureus review (section 2) and pancreatic cancer risk prediction (section 2), the publication journal and research stage cannot be confirmed just by looking at the headline.

Japanese movements

- There is no relevant information for the headings that apply to Japanese medical AI. - The following items with "diagnosis" in the heading were excluded because they are unrelated to medical care: horse racing prediction AI, cyber vulnerability diagnosis (Google DeepMind "CO-REDTEAM"), investment portfolio diagnosis, AI skeletal diagnosis. - Grassland diagnosis and dairy cow management (Obihiro University of Agriculture and Veterinary Medicine) are in the field of livestock farming, not human medicine.

Remarks from VIPs

- No relevant information because the tracked list is empty. - Reference: Regarding statements by Africa CDC officials and CPRIT CEO (paragraphs 6 and 8), only part of their title is shown in the heading, and their names are unknown. Not tracked.